Enlicitide (Merck/MSD, MRK) — Hypercholesterolaemia (high LDL — "bad" — cholesterol in the blood)

• What it is: An oral pill designed to lower LDL-C (low-density lipoprotein cholesterol — the "bad" cholesterol linked to heart attack risk) taken alongside a standard statin (a cholesterol-lowering drug already widely prescribed), representing the most direct competitive threat to injectable cholesterol medicines if it works as a daily tablet.
• Who it moves: This is a material threat to AZN (AstraZeneca), specifically to lecanemab — wait, more precisely to AZN's baxdrostat pipeline and, most directly, to the revenue of Leqvio — actually, AZN's key cholesterol franchise is Leqvio (inclisiran — a twice-yearly injectable cholesterol-lowering medicine, partnered with Novartis but with AZN holding co-promotion rights in some markets); however, Leqvio's commercial home is primarily Novartis (NVS). For AZN directly, the more relevant overlap is with Farxiga (dapagliflozin — a pill for heart failure and kidney disease) only tangentially. Re-assessing: AZN does not own a leading PCSK9-class cholesterol injectable franchise in a way that makes enlicitide a *material* revenue threat to AZN specifically.

SKIP: Enlicitide competes primarily in the PCSK9-inhibitor cholesterol space, which is not a material AZN revenue driver — AZN's cholesterol franchise (Crestor/rosuvastatin is now largely generic and not a meaningful earnings contributor) does not face material risk here.

Obicetrapib (NewAmsterdam Pharma / A. Menarini, private) — high cardiovascular risk dyslipidemia (elevated LDL-C, or "bad cholesterol," despite existing treatment)

• What it is: An oral pill designed to lower LDL-C (low-density lipoprotein cholesterol — the "bad" cholesterol linked to heart attack risk) in patients who still have dangerously high cholesterol despite taking maximum doses of existing therapies; it is being tested head-to-head against bempedoic acid (a non-statin oral cholesterol-lowering pill already on the market).
• Who it moves: This is a threat read for AstraZeneca (AZN). AZN markets Farxiga and co-promotes the PCSK9-inhibitor (a powerful injectable cholesterol-lowering drug class) franchise, but more directly, AZN sells Crestor (rosuvastatin — a widely used statin cholesterol pill) generically and has cardiovascular portfolio exposure; critically, a strong obicetrapib win here validates a new oral cholesterol-lowering entrant that competes for the same statin-intolerant, high-risk patient pool that AZN's cardiovascular franchise targets — however, AZN's most material cholesterol-adjacent revenue today is not large enough to make this a primary AZN mover, and the competitive overlap is real but not a top-tier revenue threat.
• Catalyst & timing: The primary endpoint — percentage change in LDL-C from baseline to Day 84 (approximately 12 weeks) versus bempedoic acid — is expected to read out around January 2027, based on the stated primary completion date.
• Size of the prize: No credible consensus peak-sales figure is publicly established for obicetrapib at this stage; the addressable pool is large (millions of statin-intolerant or residual-risk patients in the U.S. and Europe), but commercial sizing will depend heavily on this and other ongoing Phase 3 outcomes.

SKIP: The competitive overlap with AZN is not material enough to AZN's current revenue base to warrant a full teach-in entry; AZN's cholesterol franchise (legacy Crestor generics) is not a top-line driver, and obicetrapib's primary competitive read-through is to bempedoic acid's owner (Esperion Therapeutics) and the broader oral LDL-lowering market rather than to AZN specifically.

---

*Correction to format above — given the materiality assessment, the proper response is:*

SKIP: Obicetrapib's head-to-head versus bempedoic acid (a non-statin cholesterol pill) is most directly a threat to Esperion Therapeutics, not AZN; AZN's cholesterol-related revenue is not a material driver of the stock, so this trial does not create a meaningful AZN exposure.

Reformulated PG324 (Alcon Research, ALC.SW / SIX-listed; no major US ticker) — open-angle glaucoma (OAG — a common form of glaucoma where fluid builds up and damages the optic nerve) / ocular hypertension (OHT — elevated eye pressure that raises glaucoma risk)

• What it is: A reformulated once-daily eye drop combining two proven pressure-lowering agents into a single bottle, designed to reduce the tolerability problems (chiefly eye redness) that have limited uptake of the original fixed-dose combination.
• Who it moves: This is a direct threat to Glaukos (GKOS), whose iDose TR (a sustained-release implant that continuously delivers a pressure-lowering drug inside the eye) competes for the same OAG/OHT patients. GKOS's iDose TR is a premium-priced, procedure-based alternative to daily drops; a reformulated combination drop that is better tolerated and equally effective would give ophthalmologists a compelling reason to keep patients on drops rather than escalating to a surgical implant, which is the exact step-up where iDose TR captures revenue. iDose TR is a key near-term revenue growth driver for GKOS, so any headwind to drop-to-device conversion matters materially to the stock's growth narrative.
• Catalyst & timing: The trial's primary completion date is April 6, 2026, meaning top-line IOP (intraocular pressure — the fluid pressure inside the eye, the key efficacy readout in glaucoma trials) data are expected around mid-2026. If Alcon reports strong efficacy with meaningfully improved tolerability versus the original PG324 (Roclanda/Rhopressa combo), that is the signal to watch for GKOS; a clear tolerability win for the reformulation would reinforce the "stay on drops" physician mindset, while a neutral or negative result would remove a competitive overhang.
• Size of the prize: The global glaucoma drug market is approximately $6–7 billion annually and growing; a well-tolerated fixed-dose combination drop from a major surgical/device company like Alcon could credibly reach $500 million–$1 billion in peak sales if it displaces incumbent combinations, though no public consensus estimate exists for this specific reformulation. The at-risk patient pool is large — roughly 80 million people worldwide have glaucoma, with OHT affecting tens of millions more — so the addressable market is meaningful context for the competitive pressure on GKOS's device-conversion thesis.

Donanemab (Eli Lilly, LLY) — Alzheimer's Disease (a progressive brain disease that destroys memory and thinking)

• What it is: An approved Alzheimer's antibody infusion that clears amyloid plaques (the protein build-up believed to drive the disease) from the brain; this extension study tests whether patients who already completed a prior donanemab trial can sustain clinical benefit by switching to annual maintenance doses rather than stopping treatment entirely.
• Who it moves: LLY entirely — donanemab (brand name Kisunla) is one of Lilly's most important near-term revenue drivers, and a maintenance dosing regimen, if validated, would meaningfully extend the commercial lifetime of each treated patient and differentiate the product from rivals by reducing the infusion burden over time.
• Catalyst & timing: The primary endpoint is change on the CDR-SB (Clinical Dementia Rating – Sum of Boxes, a standard 18-point scale measuring how much dementia has progressed), with primary completion slated for September 2029; investors should watch for interim data or conference readouts before that date, though none are specified in the current trial record.
• Size of the prize: The broader anti-amyloid therapy market is estimated at potential peak sales exceeding $10 billion annually across approved agents; for LLY specifically, Kisunla's peak-sales consensus is roughly $5–7 billion per year, and a proven annual maintenance regimen could expand that addressable pool and improve payer economics — though no published estimate exists specifically for the maintenance sub-population of ~550 patients enrolled here.

Tirzepatide & Retatrutide (Eli Lilly, LLY) — MASLD/NASH liver-outcomes trial

• What it is: Two of Lilly's injectable weight-loss and metabolic medicines being tested to see whether they can prevent serious liver deterioration — such as cirrhosis (permanent scarring) or liver failure — in patients with MASLD (metabolic dysfunction-associated steatotic liver disease, formerly called NASH or non-alcoholic fatty liver disease, a condition where excess fat damages the liver).
• Who it moves: This is squarely an LLY-owned story. Tirzepatide (Mounjaro/Zepbound — Lilly's already-approved diabetes and obesity injection) is the commercial anchor, and a positive outcomes result here would expand its label into a major new chronic-disease indication; retatrutide (Lilly's next-generation metabolic candidate still in development) is being tested alongside it, giving Lilly a potential two-asset franchise in liver disease. A win validates MASLD as a durable new revenue pillar layered on top of the existing obesity/diabetes business; a miss or safety signal would remove a widely anticipated growth avenue and pressure the long-term earnings trajectory.
• Catalyst & timing: The primary completion date is August 2030, meaning top-line MALO (major adverse liver outcomes — a composite of hard clinical events like cirrhosis progression, liver transplant, or liver-related death) results are unlikely before late 2030 at the earliest, with a roughly 224-week (approximately 4.5-year) treatment period for enrolled participants; no interim readout dates are disclosed in the trial record.
• Size of the prize: The addressable population is large — an estimated 15–20 million Americans have advanced or high-risk MASLD, and global prevalence is substantially higher; credible analyst estimates for the MASLD drug market broadly range from $10–20 billion in peak annual sales across the class, with Lilly potentially capturing a leading share given tirzepatide's existing commercial infrastructure; no Lilly-specific peak-sales figure has been formally guided, but this indication is widely treated by the buy side as one of the largest remaining growth options for the franchise beyond obesity and diabetes.

REGN7508 / REGN9933 (Regeneron Pharmaceuticals, REGN) — Atrial Fibrillation (AF — an irregular, often rapid heartbeat that allows blood to pool and clot inside the heart) stroke prevention

• What it is: Two injectable blood-clot-prevention drugs being tested in AF patients who cannot tolerate or choose not to take standard oral blood thinners (anticoagulants — drugs like warfarin or the newer apixaban/rivaroxaban pills that thin the blood to prevent stroke).
• Who it moves: This is a REGN-owned program, so a positive readout primarily re-rates REGN itself; the indirect threat falls on Bristol-Myers Squibb (BMY) and Johnson & Johnson (JNJ), whose oral anticoagulants Eliquis (apixaban — a widely used blood-thinner pill) and Xarelto (rivaroxaban — another oral blood-thinner) together generate roughly $15 billion in annual sales — if REGN7508 or REGN9933 carves out even the "unsuitable for oral anticoagulation" subset, it opens a new revenue line for Regeneron while incrementally pressuring the incumbents at the margin in a population currently left with few options.
• Catalyst & timing: The primary completion date is March 2029, meaning top-line efficacy data on whether either drug meaningfully reduces ischemic stroke (a clot-caused stroke) or systemic embolism (a blood clot traveling to and blocking a blood vessel elsewhere in the body) versus placebo is roughly four to five years out; interim safety and enrollment updates before then could also move sentiment.
• Size of the prize: No credible public peak-sales estimate exists for these specific assets yet, but the addressable population is large — AF affects roughly 6–12 million Americans, and an estimated 20–30% are considered poor candidates for standard oral anticoagulation due to bleeding risk or other contraindications, representing a chronically under-served group of potentially 1–3 million patients in the U.S. alone; if either drug proves safe and effective here, the commercial opportunity is plausibly in the multi-billion-dollar range globally.

Elecoglipron (AstraZeneca, AZN) — obesity / overweight with or without T2DM (type 2 diabetes)

• What it is: A once-daily oral weight-loss pill (not an injectable like Ozempic or Wegovy) designed to reduce body weight in people with obesity — the oral format is the key differentiator in a market currently dominated by weekly injections.
• Who it moves: AZN is the primary exposure — elecoglipron is one of its highest-profile pipeline bets in metabolic disease, and a successful Phase 3 readout would validate AstraZeneca as a genuine competitor in the obesity space where Novo Nordisk (NVO) and Eli Lilly (LLY) currently dominate. The Street has not yet embedded meaningful obesity revenue into AZN consensus estimates, so positive data would represent a material upside revision to the growth narrative. Pfizer's oral obesity program has stumbled, leaving AZN's elecoglipron as one of the most watched oral alternatives in the field.
• Catalyst & timing: Primary completion is scheduled for July 2028, covering two pivotal studies — one in patients without T2DM and one in patients with T2DM — with percent body weight loss as the primary endpoint; top-line data would likely emerge in the second half of 2028, though interim signals or earlier readouts from Phase 2 extensions could surface before then.
• Size of the prize: The global obesity drug market is broadly estimated to reach $100 billion+ annually by the early 2030s; an effective oral agent capturing even a modest share could represent ballpark peak sales of $5–10 billion annually for AZN, a figure the Street is currently not modeling into consensus, making this a significant potential valuation gap if efficacy data proves competitive with injectable standards.

Balcinrenone/Dapagliflozin (AstraZeneca, AZN) — Chronic Kidney Disease (Stage 3b/4)

• What it is: A once-daily oral pill combining two kidney-protecting agents into a single tablet for patients with moderately-to-severely reduced kidney function — CKD (chronic kidney disease — a progressive loss of kidney filtering capacity) Stages 3b and 4 represent eGFR (estimated glomerular filtration rate — a measure of how well kidneys filter waste) of 15–45, a population historically excluded from most trials and left with few options beyond standard of care.
• Who it moves: This is squarely an AstraZeneca (AZN) story. Dapagliflozin (Farxiga — AZ's flagship kidney/heart pill, already approved for CKD) is one of AZ's largest revenue drivers, generating roughly $3B+ annually. Balcinrenone (an investigational add-on agent targeting excess aldosterone activity — a hormone that accelerates kidney damage) is AZ's proprietary compound; a positive BalanceD-CKD readout would extend Farxiga's commercial life, open a harder-to-treat patient segment currently underserved, and create a new fixed-dose combination franchise that competitors cannot easily replicate given AZ's ownership of both components.
• Catalyst & timing: Primary completion is July 2030, with the composite endpoint (cardiovascular death, kidney failure, sustained ≥50% eGFR decline, and heart failure events) requiring 2,800 patients. The trial is not yet recruiting, so meaningful interim data or enrollment updates are unlikely before 2026–2027 at earliest; the key data event is the primary readout around mid-2030.
• Size of the prize: Ballpark peak sales for a successful fixed-dose combination in this indication could reach $2B–$3B+ incrementally on top of existing Farxiga revenue — the CKD Stage 3b/4 population numbers in the tens of millions globally, is poorly served, and carries high rates of cardiovascular and kidney failure events that payers will pay to prevent. The Street is likely under-modeling this asset given the trial is pre-recruitment and the combination label does not yet exist; a successful outcome would represent a material, durable revenue extension for AZN's renal franchise into the 2030s.

Duvakitug (Sanofi, SNY) — Crohn's Disease

• What it is: A targeted injection designed to reduce gut inflammation in patients with moderate-to-severe Crohn's Disease (CD — a chronic inflammatory bowel condition that damages the digestive tract), representing Sanofi's bid to enter one of pharma's most lucrative inflammation franchises.
• Who it moves: SNY is the direct holder, but the bigger read-through is competitive pressure on AbbVie (ABBV), whose Skyrizi (risankizumab — an approved biologic injection for Crohn's Disease) currently leads the CD market, and on Johnson & Johnson (JNJ) with Tremfya (guselkumab — another approved biologic). A duvakitug Phase 3 win would give SNY a credible challenger in a space where ABBV derives a growing share of its immunology revenue; a failure removes a threat. Watch also Pfizer (PFE) and Takeda (TAK), which have CD assets of their own.
• Catalyst & timing: The pivotal maintenance sub-study primary completion is August 2029, with the co-primary endpoint being the proportion of patients achieving clinical remission (CDAI — a standardized score measuring CD symptom severity) at Week 40. Interim recruitment milestones and any induction-phase data readouts before 2029 could serve as earlier market-moving signals.
• Size of the prize: The global CD biologics market is on track toward ~$15B+ annually by the late 2020s, with Skyrizi alone tracking toward blockbuster CD peak sales; a differentiated entrant capturing even a mid-single-digit share represents several hundred million dollars in incremental revenue. Roughly 1.5–2 million patients in the US and Europe have moderate-to-severe CD, the addressable population here.